[The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma].
OBJECTIVE
To improve the treatment outcome of refractory midline peripheral T-cell lymphoma (MPTCL).


METHODS
Eleven patients with refractory MPTCL received salvage chemotherapy consisting of L-asparaginase(L-ASP), vincristine and dexamethosone (L-ASP group), and 10 patients received combined chemotherapy without L-ASP(control group). The response rates and 2 year survival rates were observed.


RESULTS
Response rates were 63.6% for L-ASP group and 10.0% for control group (P < 0.05), and 2 year survival rates were 45.5% and 0 (P < 0.05), respectively. The major side effects of L-ASP were leukocytopenia, elevation of serum bilirubin and hyperglycemia.


CONCLUSIONS
The L-ASP-based salvage chemotherapy improved the response rate and 2 year survival rate of the patients with refractory MPTCL.
Beijing Medical University, School of Oncology, Beijing Cancer Hospital, Beijing 100036, China.
W
W
Yong
Y
Y
Zhang
W
W
Zheng
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001216:Asparagine / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008297:Male; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D001216:Asparagine; D003907:Dexamethasone